Market: NASD |
Currency: USD
Address: 420 Lexington Avenue
Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York.Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.
📈 Citius Oncology, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$3.00
-
Upside/Downside from Analyst Target:
71.43%
-
Broker Call:
-
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
-
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Citius Oncology, Inc.
| Date | Reported EPS |
|---|
| 2025-05-14 | -0.11 |
| 2025-02-14 | -0.09 |
| 2024-12-27 | -0.1 |
📰 Related News & Research
No related articles found for "citius oncology".
